GT200800303A - Combinacion anti-retroviral - Google Patents

Combinacion anti-retroviral

Info

Publication number
GT200800303A
GT200800303A GT200800303A GT200800303A GT200800303A GT 200800303 A GT200800303 A GT 200800303A GT 200800303 A GT200800303 A GT 200800303A GT 200800303 A GT200800303 A GT 200800303A GT 200800303 A GT200800303 A GT 200800303A
Authority
GT
Guatemala
Prior art keywords
combination antiretroviral
ester
pharmaceutically acceptable
acceptable salt
darunavir
Prior art date
Application number
GT200800303A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to IN2538MU2007 priority Critical
Application filed filed Critical
Publication of GT200800303A publication Critical patent/GT200800303A/es
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfasalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04Particle-shaped
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25Component parts, details or accessories; Auxiliary operations
    • B29C48/78Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83Heating or cooling the cylinders
    • B29C48/832Heating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMBINACION ANTI-RETROVIRAL NOVEDOSA Y EN PARTICULAR UNA COMPOSICION FARMACEUTICAMENTE ESTABLE Y UN PROCESO PARA FABRICAR EL MISMO QUE COMPRENDE RITONAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE Y ESTER DEL MISMO Y DARUNAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE Y ESTER DEL MISMO.
GT200800303A 2007-12-24 2008-12-23 Combinacion anti-retroviral GT200800303A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24

Publications (1)

Publication Number Publication Date
GT200800303A true GT200800303A (es) 2009-09-18

Family

ID=54289250

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800303A GT200800303A (es) 2007-12-24 2008-12-23 Combinacion anti-retroviral

Country Status (20)

Country Link
US (1) US9339470B2 (es)
EP (2) EP2505193B1 (es)
JP (2) JP2011507940A (es)
CN (2) CN101925350B (es)
AP (2) AP2855A (es)
AT (1) AT555778T (es)
AU (1) AU2008339633A1 (es)
BR (1) BRPI0819534A2 (es)
CA (1) CA2710605C (es)
DK (1) DK2242482T3 (es)
ES (2) ES2674730T3 (es)
GT (1) GT200800303A (es)
HK (1) HK1149905A1 (es)
JO (2) JO2814B1 (es)
MX (1) MX2010007083A (es)
PA (1) PA8809601A1 (es)
PE (2) PE20091530A1 (es)
RU (2) RU2531089C2 (es)
WO (1) WO2009081174A2 (es)
ZA (1) ZA201004505B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
US8829208B2 (en) 2010-01-28 2014-09-09 Mapi Pharma Ltd. Process for the preparation of darunavir and darunavir intermediates
EP2654791A4 (en) * 2010-12-22 2014-07-09 The Feinstein Inst Medical Res Methods for treating systemic lupus erythematosus using hiv protease inhibitors
WO2013004816A1 (en) * 2011-07-07 2013-01-10 Janssen R&D Ireland Darunavir formulations
JP6122427B2 (ja) * 2011-07-07 2017-04-26 ヤンセン・サイエンシズ・アイルランド・ユーシー ダルナビル複合製剤
CA2871794A1 (en) * 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
JP2994031B2 (ja) 1988-12-20 1999-12-27 クラリティ テクノロジーズ インコーポレイテッド Hiv−1又はhiv−2抗体の存在又は量の確定方法、免疫特異的試薬、合成ペプチド、診断用キット、hiv−1又はhiv−2抗体の調製方法、免疫原及び抗体
AU4810490A (en) 1988-12-20 1990-07-10 Mawzones Developments Limited Focussing device for a microwave antenna
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein
CA2585898C (en) 1992-12-29 2009-10-20 Abbott Laboratories Use of (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4-thaizolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with another protease inhibitor for treating hiv infection
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
RU2275361C2 (ru) * 2002-11-20 2006-04-27 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
PL1765337T3 (pl) 2004-07-08 2009-02-27 Tibotec Pharm Ltd Połączenie tenofowiru, ritonawiru i TMC114
WO2006055455A1 (en) * 2004-11-16 2006-05-26 Boehringer Ingelheim International, Gmbh Method for treating hiv infection through co-administration of tipranavir and darunavir
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
RU2008128424A (ru) 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
GT200800303A (es) 2007-12-24 2009-09-18 Combinacion anti-retroviral

Also Published As

Publication number Publication date
WO2009081174A2 (en) 2009-07-02
CN103638032A (zh) 2014-03-19
AP201307064A0 (en) 2013-08-31
ES2385819T3 (es) 2012-08-01
HK1149905A1 (en) 2013-02-01
RU2014111723A (ru) 2015-10-10
JO3376B1 (ar) 2019-03-13
EP2242482A2 (en) 2010-10-27
EP2505193B1 (en) 2018-05-02
EP2505193A1 (en) 2012-10-03
EP2242482B1 (en) 2012-05-02
MX2010007083A (es) 2010-10-20
CA2710605A1 (en) 2009-07-02
CN101925350B (zh) 2014-04-30
RU2531089C2 (ru) 2014-10-20
JO2814B1 (en) 2014-09-15
CA2710605C (en) 2017-05-02
AT555778T (de) 2012-05-15
BRPI0819534A2 (pt) 2015-05-26
ES2674730T3 (es) 2018-07-03
JP2011507940A (ja) 2011-03-10
WO2009081174A3 (en) 2009-08-27
JP2015007071A (ja) 2015-01-15
ZA201004505B (en) 2013-05-29
DK2242482T3 (da) 2012-08-06
AP201005325A0 (en) 2010-08-31
US9339470B2 (en) 2016-05-17
PE20091530A1 (es) 2009-09-25
RU2675831C2 (ru) 2018-12-25
PE20140926A1 (es) 2014-08-06
US20110008429A1 (en) 2011-01-13
PA8809601A1 (es) 2009-07-23
CN101925350A (zh) 2010-12-22
AP2855A (en) 2014-02-28
AU2008339633A1 (en) 2009-07-02
RU2010131006A (ru) 2012-02-10

Similar Documents

Publication Publication Date Title
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
HN2012001321A (es) Analogo peptidico de oxintomodulina
CY1118038T1 (el) Λυοφιλισμενεσ φαρμακοτεχνικεσ μορφεσ θεραπευτικου πεπτισωματοσ
CL2011002185A1 (es) Compuestos n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)-carbamoil)benzofuran-4-iloxi)pirimidin-2-carboxamida y sus sales; composicion farmaceutica que los comprende; y su uso como activadores de la glucoquinasa para tratar la obesidad y para tratar o retrasar la progresion o el comienzo de la diabetes de tipo 2 y trastornos relacionados.
DOP2006000170A (es) Nuevos derivados de espirocromanona
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
SV2010003497A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
CO7240414A2 (es) Preparación y usos de ácido obeticólico
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
ECSP11011198A (es) Derivados de sulfonamida
GT200600297A (es) Nuevos anticuerpos anti-madcam
CU23515A3 (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
DOP2007000016A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina.
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
CL2008000411A1 (es) Composicion farmaceutica que comprende un primer compuesto que incrementa el ph del estomago, un segundo agente que reduce el ph y al menos un tercer agente seleccionado entre una vitamina, un mineral y otro farmaco; y su uso para mejorar la absorcio
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c